After breakup with Otsuka, Akebia finds new partner for oral anemia drug in Europe

Akebia Therapeutics has found a new partner in Europe for oral anemia drug Vafseo in chronic kidney disease. But the deal is smaller than the company's prior pact with Otsuka.

Medice Arzneimittel Pütter has agreed to pay Akebia $10 million upfront and up to $100 million in commercial milestones for rights to Vafseo in Europe and Australia, Akebia said Thursday.